Global Patient Derived Xenograft/PDX Models Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Patient Derived Xenograft/PDX Models Revenue
• 1.4 Market by Type
  • 1.4.1 Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Gastrointestinal Tumor Models
  • 1.4.3 Gynecological Tumor Models
  • 1.4.4 Respiratory Tumor Models
  • 1.4.5 Urological Tumor Models
  • 1.4.6 Hematological Tumor Models
• 1.5 Market by Application
  • 1.5.1 Global Patient Derived Xenograft/PDX Models Market Share by Application: 2020 VS 2026
  • 1.5.2 Pre-clinical Drug Development and Basic Cancer Research
  • 1.5.3 Biomarker Analysis
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Patient Derived Xenograft/PDX Models Market Perspective (2015-2026)
• 2.2 Global Patient Derived Xenograft/PDX Models Growth Trends by Regions
  • 2.2.1 Patient Derived Xenograft/PDX Models Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Patient Derived Xenograft/PDX Models Historic Market Share by Regions (2015-2020)
  • 2.2.3 Patient Derived Xenograft/PDX Models Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Patient Derived Xenograft/PDX Models Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Patient Derived Xenograft/PDX Models Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Patient Derived Xenograft/PDX Models Players by Market Size
  • 3.1.1 Global Top Patient Derived Xenograft/PDX Models Players by Revenue (2015-2020)
  • 3.1.2 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Patient Derived Xenograft/PDX Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio
  • 3.2.1 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Patient Derived Xenograft/PDX Models Revenue in 2019
• 3.3 Patient Derived Xenograft/PDX Models Key Players Head office and Area Served
• 3.4 Key Players Patient Derived Xenograft/PDX Models Product Solution and Service
• 3.5 Date of Enter into Patient Derived Xenograft/PDX Models Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Patient Derived Xenograft/PDX Models Historic Market Size by Type (2015-2020)
• 4.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
• 5.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 6.2 Patient Derived Xenograft/PDX Models Key Players in North America (2019-2020)
• 6.3 North America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 6.4 North America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 7.2 Patient Derived Xenograft/PDX Models Key Players in Europe (2019-2020)
• 7.3 Europe Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 7.4 Europe Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

8 China

• 8.1 China Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 8.2 Patient Derived Xenograft/PDX Models Key Players in China (2019-2020)
• 8.3 China Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 8.4 China Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 9.2 Patient Derived Xenograft/PDX Models Key Players in Japan (2019-2020)
• 9.3 Japan Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 9.4 Japan Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 10.2 Patient Derived Xenograft/PDX Models Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 10.4 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

11 India

• 11.1 India Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 11.2 Patient Derived Xenograft/PDX Models Key Players in India (2019-2020)
• 11.3 India Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 11.4 India Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
• 12.2 Patient Derived Xenograft/PDX Models Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
• 12.4 Central & South America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Crown Bioscience
  • 13.1.1 Crown Bioscience Company Details
  • 13.1.2 Crown Bioscience Business Overview
  • 13.1.3 Crown Bioscience Patient Derived Xenograft/PDX Models Introduction
  • 13.1.4 Crown Bioscience Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020))
  • 13.1.5 Crown Bioscience Recent Development
• 13.2 The Jackson Laboratory
  • 13.2.1 The Jackson Laboratory Company Details
  • 13.2.2 The Jackson Laboratory Business Overview
  • 13.2.3 The Jackson Laboratory Patient Derived Xenograft/PDX Models Introduction
  • 13.2.4 The Jackson Laboratory Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.2.5 The Jackson Laboratory Recent Development
• 13.3 Champions Oncology
  • 13.3.1 Champions Oncology Company Details
  • 13.3.2 Champions Oncology Business Overview
  • 13.3.3 Champions Oncology Patient Derived Xenograft/PDX Models Introduction
  • 13.3.4 Champions Oncology Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.3.5 Champions Oncology Recent Development
• 13.4 Charles River Laboratories
  • 13.4.1 Charles River Laboratories Company Details
  • 13.4.2 Charles River Laboratories Business Overview
  • 13.4.3 Charles River Laboratories Patient Derived Xenograft/PDX Models Introduction
  • 13.4.4 Charles River Laboratories Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.4.5 Charles River Laboratories Recent Development
• 13.5 WuXi Apptec
  • 13.5.1 WuXi Apptec Company Details
  • 13.5.2 WuXi Apptec Business Overview
  • 13.5.3 WuXi Apptec Patient Derived Xenograft/PDX Models Introduction
  • 13.5.4 WuXi Apptec Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.5.5 WuXi Apptec Recent Development
• 13.6 Oncodesign
  • 13.6.1 Oncodesign Company Details
  • 13.6.2 Oncodesign Business Overview
  • 13.6.3 Oncodesign Patient Derived Xenograft/PDX Models Introduction
  • 13.6.4 Oncodesign Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.6.5 Oncodesign Recent Development
• 13.7 Horizon Discovery
  • 13.7.1 Horizon Discovery Company Details
  • 13.7.2 Horizon Discovery Business Overview
  • 13.7.3 Horizon Discovery Patient Derived Xenograft/PDX Models Introduction
  • 13.7.4 Horizon Discovery Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.7.5 Horizon Discovery Recent Development
• 13.8 Pharmatest Services
  • 13.8.1 Pharmatest Services Company Details
  • 13.8.2 Pharmatest Services Business Overview
  • 13.8.3 Pharmatest Services Patient Derived Xenograft/PDX Models Introduction
  • 13.8.4 Pharmatest Services Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.8.5 Pharmatest Services Recent Development
• 13.9 Hera Biolabs
  • 13.9.1 Hera Biolabs Company Details
  • 13.9.2 Hera Biolabs Business Overview
  • 13.9.3 Hera Biolabs Patient Derived Xenograft/PDX Models Introduction
  • 13.9.4 Hera Biolabs Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.9.5 Hera Biolabs Recent Development
• 13.10 EPO Berlin-Buch
  • 13.10.1 EPO Berlin-Buch Company Details
  • 13.10.2 EPO Berlin-Buch Business Overview
  • 13.10.3 EPO Berlin-Buch Patient Derived Xenograft/PDX Models Introduction
  • 13.10.4 EPO Berlin-Buch Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 13.10.5 EPO Berlin-Buch Recent Development
• 13.11 Xentech
  • 10.11.1 Xentech Company Details
  • 10.11.2 Xentech Business Overview
  • 10.11.3 Xentech Patient Derived Xenograft/PDX Models Introduction
  • 10.11.4 Xentech Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 10.11.5 Xentech Recent Development
• 13.12 Urolead
  • 10.12.1 Urolead Company Details
  • 10.12.2 Urolead Business Overview
  • 10.12.3 Urolead Patient Derived Xenograft/PDX Models Introduction
  • 10.12.4 Urolead Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
  • 10.12.5 Urolead Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer